ClinicalTrials.gg
CompletedNCT00175890Updated Oct 1, 2020

A Placebo-controlled Study of Levetiracetam In Children (1mo to 4yrs of Age) With Partial Onset Seizures.

A Phase 3 interventional study of Levetiracetam and Placebo in Epilepsy, Partial, sponsored by UCB Pharma. Completed at 88 sites in 15 countries. Open to participants aged 1 Month to 4 Years. Per ClinicalTrials.gov, last updated 2020-10-01.

Sponsored by UCB Pharma (part of UCB S.A.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
116
Allocation
Randomized
Ages
1 Month to 4 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 18 studies testing levetiracetam in Epilepsies, Partial — none open to participants now, none under way, none of them phase 3. Levetiracetam · Epilepsies, Partial.

Enrollment
11th of 18
116 · median 173
Started
2004
with 4 others
Phase 3
10 of 18
none open now
Registered
8th of 18
by date
Lead sponsor
10 of 18
UCB Pharma

Among the 18 studies testing levetiracetam in Epilepsies, Partial, this one is the 11th largest by enrollment, is one of 5 that started in 2004, is one of 10 in phase 3, and was the 8th registered.

Epilepsies, Partial

243 studies on the registry are indexed under Epilepsies, Partial; 49 are open to participants now.

Browse Epilepsies, Partial studies →

Open to participants now

None of the 18 studies testing levetiracetam in Epilepsies, Partial is open now. The open studies under Epilepsies, Partial, anywhere →

About levetiracetam

Levetiracetam: first FDA approval 1999 (KEPPRA), first EMA approval 2000. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 37 Epilepsies, Partial studies recruiting now, 9 (24%) set no upper age limit and 24 (65%) stop at 75 or younger; 17 take children under 18; 3 take healthy volunteers.

This study: 1 Month to 4 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 18 studies testing levetiracetam in Epilepsies, Partial as a file.
02

Study summary

To evaluate the safety and efficacy of levetiracetam used as adjunctive treatment in pediatric subjects age 1 month to less than 4 years with partial onset seizures. Subjects will be evaluated with 48 hour inpatient video electroencephalograms (a selection and an evaluation). Other neuropsychological clinical assessments will be performed during the 34 day length of the study.

03

Conditions studied

  • Epilepsy, Partial

Browse trials for

Keywords

  • Partial Onset Seizure
  • levetiracetam
  • Video Electroencephalogram
  • Keppra
04

Who can participate

Ages eligible
1 Month to 4 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Pediatric patients from 1 month to less than 4 years of age
  • Pediatric patients diagnosed with partial onset seizures, on a stable regimen of one to two other anti-epileptic drugs and at least 2 partial onset seizures per week in the two weeks prior to screening
  • Patients must have two partial onset seizures (with corresponding clinical event) during the 48-hour video EEG at screening

Exclusion criteria

Exclusion Criteria:

  • A ketogenic diet
  • Previous exposure to levetiracetam
  • Seizures too close together to count accurately
  • Treatable seizure etiology
  • Current diagnosis of Lennox-Gastaut Syndrome or epilepsy secondary to a progressing cerebral disease
  • Diagnosis of a terminal illness
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
116 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Matching oral solution to Levetiracetam b.i.d. (twice a day) for a maximum treatment duration of 20 days.

    Other: Placebo

  • Experimental
    Levetiractem

    10 % oral solution Levetiracetam b.i.d. (twice a day) for a maximum treatment duration of 20 days.

    Drug: Levetiracetam

Interventions

  • Dosing was stratified by age. A dose of 20 mg/kg/day titrating to 40 mg/kg/day for children one month to less than six months old and a dose of 25 mg/kg/day titrating to 50 mg/kg/day for children 6 month to less than 4 years old, was used in this study. The total daily dose was administered b.i.d.

    Also known as: Keppra

  • OtherPlacebo

    Placebo solution, which is indistinguishable from the Levetiracetam oral solution.

06

What researchers measure

Primary outcomes

  1. Responder Rate for total partial onset seizures as computed from the 48-hour Evaluation video-EEG (post-baseline) and the 48-hour Selection video-EEG (baseline)

    Responder Rate is defined as the number of subjects with a ≥ 50 % reduction from baseline in their Average Daily Frequency (ADF) for partial onset seizures divided by the total number of subjects. If a subject had \< 24 hours of usable Evaluation video-EEG time (including zero time available) and withdrawal from the study with reasons linked to lack or loss of efficacy, the subject was counted as a non-responder.

    Time frame: 48-hours in Evaluation Period and 48-hours in Selection Period

Secondary outcomes

  1. Responder rate for total seizures (all types) as computed from the 48-hour Evaluation video-EEG (post-baseline) and the 48-hour Selection video-EEG (baseline)

    Responder Rate is defined as the number of subjects with a ≥ 50 % reduction from baseline in their Average Daily Frequency (ADF) for all seizure types divided by the total number of subjects. Subjects who withdrew or dropped out before the first 24 hours Evaluation video-EEG with reasons linked to lack of efficacy were considered as non-responders. All (total) seizures were defined as the total of Type I (partial onset) + Type II (Primary generalized) + Type III (unclassified epileptic).

    Time frame: 48-hours in Evaluation Period and 48-hours in Selection Period

  2. Percent reduction in Average Daily Frequency (ADF) of partial onset seizures recorded on the 48-hour Evaluation video-EEG compared to those recorded on the 48-hour Selection video-EEG

    A positive value in Percent reduction from Selection Period to Evaluation Period indicates an improvement.

    Time frame: 48-hours in Evaluation Period and 48-hours in Selection Period

  3. Percent reduction in Average Daily Frequency (ADF) of total seizures (all types) recorded on the 48-hour Evaluation video-EEG compared to those recorded on the 48-hour Selection video-EEG

    A positive value in Percent reduction from Selection Period to Evaluation Period indicates an improvement. All (total) seizures were defined as the total of Type I (partial onset) + Type II (Primary generalized) + Type III (unclassified epileptic).

    Time frame: 48-hours in Evaluation Period and 48-hours in Selection Period

  4. Absolute reduction in Average Daily Frequency (ADF) of partial onset seizures recorded on the 48-hour Evaluation video-EEG compared to those recorded on the 48-hour Selection video-EEG

    A positive value in Absolute reduction from Selection Period to Evaluation Period indicates an improvement.

    Time frame: 48-hours in Evaluation Period and 48-hours in Selection Period

  5. Absolute reduction in Average Daily Frequency (ADF) of total seizures (all types) recorded on the 48-hour Evaluation video-EEG compared to those recorded on the 48-hour Selection video-EEG

    A positive value in Absolute reduction from Selection Period to Evaluation Period indicates an improvement. All (total) seizures were defined as the total of Type I (partial onset) + Type II (Primary generalized) + Type III (unclassified epileptic).

    Time frame: 48-hours in Evaluation Period and 48-hours in Selection Period

  6. Percent reduction in Average Daily Frequency (ADF) of electro-clinical partial onset seizures recorded on the 48-hour Evaluation video-EEG compared to those recorded on the 48-hour Selection video-EEG for children 1 month to less than 6 months old

    A positive value in Percent reduction from Selection Period to Evaluation Period indicates an improvement. For children 1 month to less than 6 months old, partial onset seizure counts were based on electroclinical seizures plus electrographic seizures.

    Time frame: 48-hours in Evaluation Period and 48-hours in Selection Period

  7. Percentage of drop-outs for any reasons during the study

    Time frame: During the study (up to 20 days)

  8. Percentage of drop-outs due to lack of efficacy during the study

    Time frame: During the study (up to 20 days)

  9. Percentage of drop-outs before 24 hours of Evaluation video-EEG for reasons other than lack or loss of efficacy

    Time frame: During the study (up to 20 days)

  10. Time to Exit (TTE) during the Evaluation Period

    For early termination subjects in the Evaluation period the TTE is the time to discontinuing the study for any reason. TTE was defined as the day of study discontinuation - the day of randomization + 1. For completed subjects, the TTE was censored on Day 6.

    Time frame: During Evaluation Period (Day 1 to Day 6)

07

Study locations

88 sites
  • Birmingham, Alabama, United States
  • Mobile, Alabama, United States
  • Tucson, Arizona, United States
  • Little Rock, Arkansas, United States
  • Los Angeles, California, United States
  • Gainesville, Florida, United States
  • Loxahatchee Groves, Florida, United States
  • Miami, Florida, United States
  • Tallahassee, Florida, United States
  • Tampa, Florida, United States
  • Augusta, Georgia, United States
  • Boise, Idaho, United States
  • Chicago, Illinois, United States
  • New Orleans, Louisiana, United States
  • Boston, Massachusetts, United States
  • Detroit, Michigan, United States
  • Saint Paul, Minnesota, United States
  • Lebanon, New Hampshire, United States
  • Cherry Hill, New Jersey, United States
  • Edison, New Jersey, United States
  • Buffalo, New York, United States
  • New York, New York, United States
  • Rochester, New York, United States
  • Syracuse, New York, United States
  • Chapel Hill, North Carolina, United States
  • Winston-Salem, North Carolina, United States
  • Cincinnati, Ohio, United States
  • Cleveland, Ohio, United States
  • Columbus, Ohio, United States
  • Portland, Oregon, United States
  • Danville, Pennsylvania, United States
  • Hershey, Pennsylvania, United States
  • Philadelphia, Pennsylvania, United States
  • Spartanburg, South Carolina, United States
  • Nashville, Tennessee, United States
  • Dallas, Texas, United States
  • Fort Worth, Texas, United States
  • Salt Lake City, Utah, United States
  • Richmond, Virginia, United States
  • Seattle, Washington, United States
  • Morgantown, West Virginia, United States
  • Milwaukee, Wisconsin, United States
  • Buenos Aires, Argentina
  • Mendoza, Argentina
  • Pilar Buenos Aires, Argentina
  • Brussels, Belgium
  • Leuven, Belgium
  • Campinas, Brazil
  • Curitiba, Brazil
  • Porto Alegre, Brazil
  • Ribeirao Preto, Brazil
  • Rio de Janeiro, Brazil
  • Sao Paulo, Brazil
  • Vancouver, British Columbia, Canada
  • Winnepeg, Manitoba, Canada
  • St John's, Newfoundland and Labrador, Canada
  • London, Ontario, Canada
  • Scarborough, Ontario, Canada
  • Saskatoon, Saskatchewan, Canada
  • Brno, Czechia
  • Praha 4, Czechia
  • Praha 5, Czechia
  • Lille Cedex, France
  • Paris, France
  • Rouen Cedex, France
  • Strasbourg Cedex, France
  • Kehl, Kork, Germany
  • Berlin, Germany
  • Erlangen, Germany
  • Heidelberg, Germany
  • Jena, Germany
  • Kiel, Germany
  • Budapest, Hungary
  • Calambrone, Italy
  • Genoa, Italy
  • Milano, Italy
  • Roma, Italy
  • Mexico City, Mexico
  • Gdansk, Poland
  • Bucharest, Romania
  • Cluj-Napoca, Romania
  • Tirgu-Mures, Romania
  • Kalingrad, Russian Federation
  • Moscow, Russian Federation
  • Saint Petersburg, Russian Federation
  • St Petersburg, Russian Federation
  • Glasgow, United Kingdom
  • London, United Kingdom
08

References and documents

Publications

  • Pina-Garza JE, Nordli DR Jr, Rating D, Yang H, Schiemann-Delgado J, Duncan B; Levetiracetam N01009 Study Group. Adjunctive levetiracetam in infants and young children with refractory partial-onset seizures. Epilepsia. 2009 May;50(5):1141-9. doi: 10.1111/j.1528-1167.2008.01981.x. Epub 2009 Feb 21. PubMed 19243423 ↗
  • Pina-Garza JE, Schiemann-Delgado J, Yang H, Duncan B, Hadac J, Hunter SJ. Adjunctive levetiracetam in patients aged 1 month to <4 years with partial-onset seizures: subpopulation analysis of a prospective, open-label extension study of up to 48 weeks. Clin Ther. 2010 Oct;32(11):1935-50. doi: 10.1016/j.clinthera.2010.09.017. PubMed 21095488 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2004, a primary completion of Jan 2007 and a completion of Jan 2007. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 9, 2005
First posted
Sep 15, 2005
Start
Oct 2004
Primary completionActual
Jan 2007
CompletionActual
Jan 2007
Last update
Oct 1, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 1, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00175890
Lead sponsor
UCB Pharma
Responsible party
Sponsor
First posted
Sep 15, 2005
Start date
Oct 2004
Primary completion
Jan 2007
Completion
Jan 2007
Last update
Oct 1, 2020

Study contacts

UCB Clinical Trial Call Center
study director · UCB Pharma

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Levetiracetam

Start the discussion